Aortic regurgitation overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:


==Overview of Aortic Insufficiency==
==Overview of Aortic Insufficiency==
'''Aortic Insufficiency''' refers to retrograde or backwards flow of blood from the aorta into the left ventricle during diastole<ref name="pmid9271479">{{cite journal |author=Connolly HM, Crary JL, McGoon MD, ''et al'' |title=Valvular heart disease associated with fenfluramine-phentermine |journal=N. Engl. J. Med. |volume=337 |issue=9 |pages=581–8 |year=1997 |pmid=9271479 |doi=10.1056/NEJM199708283370901|url=http://content.nejm.org/cgi/content/full/337/9/581}}</ref> <ref name="pmid11307869">{{cite journal |author=Weissman NJ |title=Appetite suppressants and valvular heart disease |journal=Am. J. Med. Sci. |volume=321 |issue=4 |pages=285–91 |year=2001 |pmid=11307869|doi=10.1097/00000441-200104000-00008}}</ref> <ref name="pmid17202453">{{cite journal |author=Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E |title=Dopamine agonists and the risk of cardiac-valve regurgitation |journal=N. Engl. J. Med. |volume=356 |issue=1 |pages=29–38 |year=2007 |pmid=17202453 |doi=10.1056/NEJMoa062222}}</ref> <ref name="pmid17202454">{{cite journal |author=Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G |title=Valvular heart disease and the use of dopamine agonists for Parkinson's disease |journal=N. Engl. J. Med. |volume=356 |issue=1 |pages=39–46 |year=2007 |pmid=17202454 |doi=10.1056/NEJMoa054830}}</ref>.
'''Aortic Insufficiency''' refers to the retrograde or backwards flow of blood from the [[aorta]] into the [[left ventricle]] during [[diastole]]<ref name="pmid9271479">{{cite journal |author=Connolly HM, Crary JL, McGoon MD, ''et al'' |title=Valvular heart disease associated with fenfluramine-phentermine |journal=N. Engl. J. Med. |volume=337 |issue=9 |pages=581–8 |year=1997 |pmid=9271479 |doi=10.1056/NEJM199708283370901|url=http://content.nejm.org/cgi/content/full/337/9/581}}</ref> <ref name="pmid11307869">{{cite journal |author=Weissman NJ |title=Appetite suppressants and valvular heart disease |journal=Am. J. Med. Sci. |volume=321 |issue=4 |pages=285–91 |year=2001 |pmid=11307869|doi=10.1097/00000441-200104000-00008}}</ref> <ref name="pmid17202453">{{cite journal |author=Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E |title=Dopamine agonists and the risk of cardiac-valve regurgitation |journal=N. Engl. J. Med. |volume=356 |issue=1 |pages=29–38 |year=2007 |pmid=17202453 |doi=10.1056/NEJMoa062222}}</ref> <ref name="pmid17202454">{{cite journal |author=Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G |title=Valvular heart disease and the use of dopamine agonists for Parkinson's disease |journal=N. Engl. J. Med. |volume=356 |issue=1 |pages=39–46 |year=2007 |pmid=17202454 |doi=10.1056/NEJMoa054830}}</ref>.


===Etiology===
===Causes of Aortic Insufficiency===
*'''Aortic valve disease:'''
There are two broad causes of aortic insufficiency: diseases of the [[aortic valve]] itself and diseases of the [[aorta]].
**[[Rheumatic fever]] causes retraction of the cusps with resultant mixed [[aortic stenosis]] and aortic insufficiency with involvement of [[mitral valve]] disease.
**[[Infective endocarditis]]
**[[Traumatic aortic rupture]] following blunt chest trauma or deceleration injury.
**Congenital [[bicuspid aortic valve]] associated with increased risk of [[aortic dissection]] which then leads to aortic insufficiency.
**Dopamine agonists<ref name="pmid17202453">{{cite journal |author=Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E |title=Dopamine agonists and the risk of cardiac-valve regurgitation |journal=[[The New England Journal of Medicine]] |volume=356 |issue=1 |pages=29–38 |year=2007 |month=January |pmid=17202453 |doi=10.1056/NEJMoa062222 |url=http://dx.doi.org/10.1056/NEJMoa062222 |accessdate=2011-03-28}}</ref><ref name="pmid11104741">{{cite journal |author=Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL |title=Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications |journal=[[Circulation]] |volume=102 |issue=23 |pages=2836–41 |year=2000 |month=December |pmid=11104741 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11104741 |accessdate=2011-03-28}}</ref><ref name="pmid16092580">{{cite journal |author=Waller EA, Kaplan J, Heckman MG |title=Valvular heart disease in patients taking pergolide |journal=[[Mayo Clinic Proceedings. Mayo Clinic]] |volume=80 |issue=8 |pages=1016–20 |year=2005 |month=August |pmid=16092580 |doi= |url=http://www.mayoclinicproceedings.com/cgi/pmidlookup?view=long&pmid=16092580 |accessdate=2011-03-28}}</ref>


*'''Aortic root disease:'''
====Aortic valve disease====
**[[Hypertension]]
*[[Rheumatic fever]] causes retraction of the cusps with resultant mixed [[aortic stenosis]] and aortic insufficiency with involvement of [[mitral valve]] disease.
**[[Aortic dissection]]
*[[Infective endocarditis]]
**[[Marfan syndrome]]
*[[Traumatic aortic rupture]] following blunt chest trauma or deceleration injury.
**HLA B-27 positive conditions : [[Psoriatic arthritis]] ; [[Ankylosing spondylitis]] ; [[Reiter's syndrome]]
*Congenital [[bicuspid aortic valve]] associated with increased risk of [[aortic dissection]] which then leads to aortic insufficiency.
**[[Giant cell arteritis]]  
*Dopamine agonists<ref name="pmid17202453">{{cite journal |author=Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E |title=Dopamine agonists and the risk of cardiac-valve regurgitation |journal=[[The New England Journal of Medicine]] |volume=356 |issue=1 |pages=29–38 |year=2007 |month=January |pmid=17202453 |doi=10.1056/NEJMoa062222 |url=http://dx.doi.org/10.1056/NEJMoa062222 |accessdate=2011-03-28}}</ref><ref name="pmid11104741">{{cite journal |author=Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL |title=Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications |journal=[[Circulation]] |volume=102 |issue=23 |pages=2836–41 |year=2000 |month=December |pmid=11104741 |doi= |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11104741 |accessdate=2011-03-28}}</ref><ref name="pmid16092580">{{cite journal |author=Waller EA, Kaplan J, Heckman MG |title=Valvular heart disease in patients taking pergolide |journal=[[Mayo Clinic Proceedings. Mayo Clinic]] |volume=80 |issue=8 |pages=1016–20 |year=2005 |month=August |pmid=16092580 |doi= |url=http://www.mayoclinicproceedings.com/cgi/pmidlookup?view=long&pmid=16092580 |accessdate=2011-03-28}}</ref>
**[[Syphilitic aortitis]]
 
====Aortic root disease====
*[[Hypertension]]
*[[Aortic dissection]]
*[[Marfan syndrome]]
*HLA B-27 positive conditions : [[Psoriatic arthritis]] ; [[Ankylosing spondylitis]] ; [[Reiter's syndrome]]
*[[Giant cell arteritis]]  
*[[Syphilitic aortitis]]


===Pathophysiology===
===Pathophysiology===
In acute aortic insufficiency, there is sudden decrease in [[stroke volume]] and subsequent '''increase in left ventricular end diastolic volume''' thereby causing decrease [[cardiac output]] with resultant reflex [[tachycardia]]. The sharply rising high left ventricular end diastolic pressure and reflex tachycardia causes profound [[hypotension]] and [[cardiogenic shock]].
====Acute Pathophysiology====
Initially, the rising [[left ventricle end diastolic pressure]] causes early closure of [[mitral valve]] during diastole thereby preventing backward blood flow. But in severe cases, the rapidly rising [[left ventricular end diastolic pressure]] equalizes with the aortic end-diastolic pressure leading to backward flow of blood progressing towards development of [[pulmonary edema]].
In acute aortic insufficiency, there is sudden decrease in [[stroke volume]] and subsequent '''increase in left ventricular end diastolic volume''' thereby causing decrease [[cardiac output]] with resultant reflex [[tachycardia]]. The sharply rising high left ventricular end diastolic pressure and reflex tachycardia causes profound [[hypotension]] and [[cardiogenic shock]]. Initially, the rising [[left ventricle end diastolic pressure]] causes early closure of [[mitral valve]] during diastole thereby preventing backward blood flow. But in severe cases, the rapidly rising [[left ventricular end diastolic pressure]] equalizes with the aortic end-diastolic pressure leading to backward flow of blood progressing towards development of [[pulmonary edema]].


In chronic aortic insufficiency, initially the left ventricle remains complaint, thereby compensates for  increased left ventricular end diastolic volume by progressive left ventricular dilatation and [[left ventricular hypertrophy]], which maintains normal ratio of wall thickness to the cavity radius, thereby maintaining normal wall stress.
====Chronic Pathophysiology====
Overtime, when the [[left ventricular hypertrophy]] fails to keep up with chronic volume overload, end systolic wall stress rises and at this point the left ventricle fails and results in left ventricle decompensation causing reduction in the left ventricular wall compliance with resultant [[congestive heart failure]].
In chronic aortic insufficiency, initially the left ventricle remains complaint, thereby compensates for  increased left ventricular end diastolic volume by progressive left ventricular dilatation and [[left ventricular hypertrophy]], which maintains normal ratio of wall thickness to the cavity radius, thereby maintaining normal wall stress. Overtime, when the [[left ventricular hypertrophy]] fails to keep up with chronic volume overload, end systolic wall stress rises and at this point the left ventricle fails and results in left ventricle decompensation causing reduction in the left ventricular wall compliance with resultant [[congestive heart failure]].


===Diagnosis===  
===Diagnosis===  
* ECG : [[left ventricular hypertrophy]] , [[left axis deviation]]
====Electrocardiogram====
* Chest XR : [[cardiomegaly]]
There is often evidence of [[left ventricular hypertrophy]] and [[left axis deviation]].
* [[Echocardiogram]] : most common test used which provides two-dimensional views of the regurgitant jet, allows measure the velocity and volume of the jet. In severe aortic insufficiency, '''regurgitant jet width is more than 65% [[LVOT]]''' or there is a '''flow reversal in the descending aorta'''.
 
* Cardiac MRI and Aortography: to quantify aortic insufficiency
====Chest X Ray====
There may be evidence of [[cardiomegaly].
 
====Echocardiography====
Echocardiography provides two-dimensional views of the regurgitant jet and allows measurement of both the velocity and the volume of the jet. In severe aortic insufficiency, the regurgitant jet width is more than 65% of the width of the left ventricular outflow tract  ([[LVOT]]) and / or there is flow reversal in the descending aorta.
 
====Aortography====
A root shot on the aortogram can be used to gauge the amount of aortic insufficiency.
 
====Cardiac MRI====
Cardiac MRI can be used to quantify aortic insufficiency.


===Treatment===
===Treatment===
Aortic insufficiency can be treated either medically with [[vasodilators]] or surgically with [[aortic valve replacement]], depending on the acuteness of presentation, the symptoms and signs associated with the disease process, and the degree of [[left ventricular dysfunction]].
Aortic insufficiency can be treated either medically with [[vasodilators]] or surgically with [[aortic valve replacement]], depending on the acuteness of presentation, the symptoms and signs associated with the disease process, and the degree of [[left ventricular dysfunction]].


In general, acute aortic insufficiency with [[left ventricular dysfunction]], symptomatic severe aortic insufficiency, asymptomatic aortic insufficiency with [[left ventricular dilatation]] or [[ejection fraction]] < 50% or undergoing cardiac surgery should be treated surgically with [[aortic valve replacement]] if there are no contraindications.
In general, acute aortic insufficiency with [[left ventricular dysfunction]], symptomatic severe aortic insufficiency, asymptomatic aortic insufficiency with [[left ventricular dilatation]] or [[ejection fraction]] < 50% should be treated surgically with [[aortic valve replacement]] if there are no contraindications.


Chronic aortic insufficiency is managed with [[vasodilators]] <ref name="pmid16192479">{{cite journal |author=Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J |title=Long-term vasodilator therapy in patients with severe aortic regurgitation |journal=[[The New England Journal of Medicine]] |volume=353 |issue=13 |pages=1342–9 |year=2005 |month=September |pmid=16192479 |doi=10.1056/NEJMoa050666 |url=http://dx.doi.org/10.1056/NEJMoa050666 |accessdate=2011-03-29}}</ref> such as [[ACE inhibitors]] , [[hydralazine]] or [[nifidipine]] to reduce the [[afterload]].  Indications for surgery in chronic aortic insufficiency include [[heart failure]] with a reduced [[ejection fraction]] and increased left ventricular dimensions.  
Chronic aortic insufficiency is managed with [[vasodilators]] <ref name="pmid16192479">{{cite journal |author=Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J |title=Long-term vasodilator therapy in patients with severe aortic regurgitation |journal=[[The New England Journal of Medicine]] |volume=353 |issue=13 |pages=1342–9 |year=2005 |month=September |pmid=16192479 |doi=10.1056/NEJMoa050666 |url=http://dx.doi.org/10.1056/NEJMoa050666 |accessdate=2011-03-29}}</ref> such as [[ACE inhibitors]] , [[hydralazine]] or [[nifidipine]] to reduce the [[afterload]].  Indications for surgery in chronic aortic insufficiency include [[heart failure]] with a reduced [[ejection fraction]] and increased left ventricular dimensions.  

Revision as of 18:34, 7 April 2011

WikiDoc Resources for Aortic regurgitation overview

Articles

Most recent articles on Aortic regurgitation overview

Most cited articles on Aortic regurgitation overview

Review articles on Aortic regurgitation overview

Articles on Aortic regurgitation overview in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aortic regurgitation overview

Images of Aortic regurgitation overview

Photos of Aortic regurgitation overview

Podcasts & MP3s on Aortic regurgitation overview

Videos on Aortic regurgitation overview

Evidence Based Medicine

Cochrane Collaboration on Aortic regurgitation overview

Bandolier on Aortic regurgitation overview

TRIP on Aortic regurgitation overview

Clinical Trials

Ongoing Trials on Aortic regurgitation overview at Clinical Trials.gov

Trial results on Aortic regurgitation overview

Clinical Trials on Aortic regurgitation overview at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aortic regurgitation overview

NICE Guidance on Aortic regurgitation overview

NHS PRODIGY Guidance

FDA on Aortic regurgitation overview

CDC on Aortic regurgitation overview

Books

Books on Aortic regurgitation overview

News

Aortic regurgitation overview in the news

Be alerted to news on Aortic regurgitation overview

News trends on Aortic regurgitation overview

Commentary

Blogs on Aortic regurgitation overview

Definitions

Definitions of Aortic regurgitation overview

Patient Resources / Community

Patient resources on Aortic regurgitation overview

Discussion groups on Aortic regurgitation overview

Patient Handouts on Aortic regurgitation overview

Directions to Hospitals Treating Aortic regurgitation overview

Risk calculators and risk factors for Aortic regurgitation overview

Healthcare Provider Resources

Symptoms of Aortic regurgitation overview

Causes & Risk Factors for Aortic regurgitation overview

Diagnostic studies for Aortic regurgitation overview

Treatment of Aortic regurgitation overview

Continuing Medical Education (CME)

CME Programs on Aortic regurgitation overview

International

Aortic regurgitation overview en Espanol

Aortic regurgitation overview en Francais

Business

Aortic regurgitation overview in the Marketplace

Patents on Aortic regurgitation overview

Experimental / Informatics

List of terms related to Aortic regurgitation overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview of Aortic Insufficiency

Aortic Insufficiency refers to the retrograde or backwards flow of blood from the aorta into the left ventricle during diastole[1] [2] [3] [4].

Causes of Aortic Insufficiency

There are two broad causes of aortic insufficiency: diseases of the aortic valve itself and diseases of the aorta.

Aortic valve disease

Aortic root disease

Pathophysiology

Acute Pathophysiology

In acute aortic insufficiency, there is sudden decrease in stroke volume and subsequent increase in left ventricular end diastolic volume thereby causing decrease cardiac output with resultant reflex tachycardia. The sharply rising high left ventricular end diastolic pressure and reflex tachycardia causes profound hypotension and cardiogenic shock. Initially, the rising left ventricle end diastolic pressure causes early closure of mitral valve during diastole thereby preventing backward blood flow. But in severe cases, the rapidly rising left ventricular end diastolic pressure equalizes with the aortic end-diastolic pressure leading to backward flow of blood progressing towards development of pulmonary edema.

Chronic Pathophysiology

In chronic aortic insufficiency, initially the left ventricle remains complaint, thereby compensates for increased left ventricular end diastolic volume by progressive left ventricular dilatation and left ventricular hypertrophy, which maintains normal ratio of wall thickness to the cavity radius, thereby maintaining normal wall stress. Overtime, when the left ventricular hypertrophy fails to keep up with chronic volume overload, end systolic wall stress rises and at this point the left ventricle fails and results in left ventricle decompensation causing reduction in the left ventricular wall compliance with resultant congestive heart failure.

Diagnosis

Electrocardiogram

There is often evidence of left ventricular hypertrophy and left axis deviation.

Chest X Ray

There may be evidence of [[cardiomegaly].

Echocardiography

Echocardiography provides two-dimensional views of the regurgitant jet and allows measurement of both the velocity and the volume of the jet. In severe aortic insufficiency, the regurgitant jet width is more than 65% of the width of the left ventricular outflow tract (LVOT) and / or there is flow reversal in the descending aorta.

Aortography

A root shot on the aortogram can be used to gauge the amount of aortic insufficiency.

Cardiac MRI

Cardiac MRI can be used to quantify aortic insufficiency.

Treatment

Aortic insufficiency can be treated either medically with vasodilators or surgically with aortic valve replacement, depending on the acuteness of presentation, the symptoms and signs associated with the disease process, and the degree of left ventricular dysfunction.

In general, acute aortic insufficiency with left ventricular dysfunction, symptomatic severe aortic insufficiency, asymptomatic aortic insufficiency with left ventricular dilatation or ejection fraction < 50% should be treated surgically with aortic valve replacement if there are no contraindications.

Chronic aortic insufficiency is managed with vasodilators [7] such as ACE inhibitors , hydralazine or nifidipine to reduce the afterload. Indications for surgery in chronic aortic insufficiency include heart failure with a reduced ejection fraction and increased left ventricular dimensions.

References

  1. Connolly HM, Crary JL, McGoon MD; et al. (1997). "Valvular heart disease associated with fenfluramine-phentermine". N. Engl. J. Med. 337 (9): 581–8. doi:10.1056/NEJM199708283370901. PMID 9271479.
  2. Weissman NJ (2001). "Appetite suppressants and valvular heart disease". Am. J. Med. Sci. 321 (4): 285–91. doi:10.1097/00000441-200104000-00008. PMID 11307869.
  3. 3.0 3.1 Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007). "Dopamine agonists and the risk of cardiac-valve regurgitation". N. Engl. J. Med. 356 (1): 29–38. doi:10.1056/NEJMoa062222. PMID 17202453.
  4. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007). "Valvular heart disease and the use of dopamine agonists for Parkinson's disease". N. Engl. J. Med. 356 (1): 39–46. doi:10.1056/NEJMoa054830. PMID 17202454.
  5. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (2000). "Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications". Circulation. 102 (23): 2836–41. PMID 11104741. Retrieved 2011-03-28. Unknown parameter |month= ignored (help)
  6. Waller EA, Kaplan J, Heckman MG (2005). "Valvular heart disease in patients taking pergolide". Mayo Clinic Proceedings. Mayo Clinic. 80 (8): 1016–20. PMID 16092580. Retrieved 2011-03-28. Unknown parameter |month= ignored (help)
  7. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J (2005). "Long-term vasodilator therapy in patients with severe aortic regurgitation". The New England Journal of Medicine. 353 (13): 1342–9. doi:10.1056/NEJMoa050666. PMID 16192479. Retrieved 2011-03-29. Unknown parameter |month= ignored (help)

Template:WH Template:WS